ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.95M | -15.01M | -15.56M | -24.12M | -24.36M |
| Total Depreciation and Amortization | 1.22M | 1.59M | 1.95M | 2.06M | 2.07M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.35M | 6.16M | 6.02M | 14.41M | 14.31M |
| Change in Net Operating Assets | 1.29M | 1.63M | 995.00K | -22.60K | 1.06M |
| Cash from Operations | -5.10M | -5.62M | -6.60M | -7.66M | -6.93M |
| Capital Expenditure | -7.90K | -7.90K | -7.90K | -7.20K | -8.80K |
| Sale of Property, Plant, and Equipment | 0.00 | 18.10K | 18.10K | 18.10K | 18.10K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Investing | -7.90K | 10.20K | 10.20K | 10.90K | 9.30K |
| Total Debt Issued | 4.81M | 3.83M | 4.15M | 8.50M | 7.15M |
| Total Debt Repaid | -327.00K | -393.00K | -396.00K | -314.00K | -2.86M |
| Issuance of Common Stock | 1.44M | 3.01M | 3.01M | 2.54M | 5.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 824.00K | 788.00K | 788.00K | -- | -- |
| Cash from Financing | 4.85M | 5.22M | 5.41M | 7.68M | 6.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -259.20K | -393.50K | -1.17M | 29.30K | -186.20K |